It is currently unclear whether the therapeutic activity of these compounds in leukemia is primarily due to selective Aurora or multi-kinase inhibition. The most promising application for Aurora ...

The research – published in the Journal of Cell Science – will be of interest to scientists around the world looking at Aurora inhibitors; there are currently more than 10 companies pursuing ...

BOSTON--(BUSINESS WIRE)--VITRAC Therapeutics, LLC (VITRAC) presented a poster on the Phase 1a/1b clinical trial of aurora kinase A (AURKA) inhibitor, VIC-1911, as monotherapy and in combination ...

Jacobio Pharmaceuticals announced that it's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in ...

VIC-1911 is an oral selective Aurora kinase A inhibitor (AURKA). The trial is being carried out at the University of Minnesota Medical School, Hematology and Transplantation, with Shernan G.

Aurora A overexpression correlates with poor prognosis and is considered a therapeutic target for cancer treatments, although the clinical development of Aurora kinase inhibitors has been so far ...

Co announces the presentation of preclinical results for its Aurora kinase - angiogenesis inhibitor, ENMD-981693. In preclinical studies, ENMD-981693 has been shown to inhibit a unique profile of ...

Vertex Pharmaceuticals Inc.'s collaboration with Merck & Co. Inc. to develop Aurora kinase inhibitors in cancer encountered a bump in the road after preliminary safety data indicated a potential ...